EP1904654A2 — Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
Assigned to Bristol Myers Squibb Co · Expires 2008-04-02 · 18y expired
What this patent protects
The invention described herein relates to mutant SRC kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant SRC kinase proteins.
USPTO Abstract
The invention described herein relates to mutant SRC kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant SRC kinase proteins.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.